Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

Inclusion Criteria: * Male or female ≥18 and ≤75 years of age hospitalized with ASUC (Mayo score \>10 or Truelove and Witts criteria) * Diagnosis of UC for at least 90 days, confirmed by colonoscopy; appropriate documentation of biopsy results consistent with the diagnosis of UC * No prior use of upadacitinib * Capable of providing informed consent * For women of childbearing potential: negative pregnancy test at screening and agreement to use acceptable contraception throughout study participation Exclusion Criteria: * • Current diagnosis of Crohn's disease, indeterminate colitis, fulminant colitis, and/or toxic megacolon * Disease limited to the rectum during screening endoscopy * History of colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or was planning bowel surgery * Infections requiring treatment with IV anti-infectives within 30 days before baseline or oral anti-infectives within 14 days before baseline * Contraindication to IL-23 agent if advanced therapy-naïve * Known hypersensitivity to upadacitinib or any excipients * History of lymphoproliferative disorder, lymphoma, leukemia, or any malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ * History of venous thromboembolic event (DVT, PE) within past 12 months * Any condition that, in the investigator's opinion, would compromise the participant's safety or study outcomes * History of clinically significa…